drugset / Trial / NCT03023787
Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the safety and tolerability of Hepalatide(L47) and characterize the clinical pharmacokinetics in healthy volunteers.
Timeline
- Start
- 2016-08
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hepalatide | Protein / enzyme biologic | 4.2 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 6.3 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 8.4 mg | Subcutaneous |